Quarterly results round-up: LabCorp, Bard hit by legal costs; Edwards, Intuitive grow top and bottom lines
This article was originally published in Clinica
Executive Summary
CR Bard swung to a net loss of $47.8m in its fiscal second quarter as it absorbed $195.5m in litigation charges related to its recalled hernia products. The products include the Composix Kugel mesh hernia patch, which its Davol subsidiary recalled in 2006 due to a risk of the patch breaking and damaging patients' internal organs (www.clinica.co.uk, 10 March 2006).
You may also be interested in...
What are the hottest innovations from Israel?
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
EuroPCR: St Jude and Philips talk up rival intravascular imaging techs
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
EuroPCR: Medtronic's drug-coated balloon keeps rising
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.